Page 2,982«..1020..2,9812,9822,9832,984..2,9903,000..»

New Report Details Uphill Battle to Solve the U.S.’s Pain Problem

Posted: July 24, 2011 at 4:04 pm

Chronic pain affects at least one in three adults in the U.S., which is more than the sum total of those with heart disease, cancer and diabetes combined. For many of these 116 million Americans, their pain is severe and eludes available treatments. In addition to the human suffering, the monetary cost of medical treatment and lost productivity has reached $635 billion a year. [More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Posted in Gene therapy | Comments Off on New Report Details Uphill Battle to Solve the U.S.’s Pain Problem

The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

Posted: July 24, 2011 at 4:04 pm

International Stem Cell Corp (OTCBB: ISCO), a biotechnology company focused on therapeutic biomedical research and cosmeceutical products, operating in the same industry as companies like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC), aims to become the premier supplier of human cells and cell based products to the rapidly growing regenerative medicine industry.
International Stem Cell Corp (OTCBB: ISCO) specializes in manufacturing pluripotent human “partheno-genetic” stem cells that can be converted into any of the many specific types of cells that will be needed as regenerative medicine moves from the laboratory to the hospital or physician’s office.  ISCO’s cells have the same kind of ability to become any specific cell that might be needed for therapy as do the cells used by competitors like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC). Unlike the cells used by these competitors, however, ISCO’s cells are not obtained from fertilized embryos that might otherwise mature into a human child. Instead, they are derived from un-fertilized human eggs that would otherwise be destroyed and have no capacity to become a human child. Thus, ISCO’s parthenogenetic stem cells have removed a major ethical barrier to the use of the most prolific class of stem cells available to science today. With its patent on using the parthenogenesis process to make the stem cells, the company plans to establish partnerships, collaborations and licensing agreements with larger pharmaceutical companies to eventually unlock significant shareholder value.
Please read the complete article at The OTC Investor here
Posted in Stem Cells, Stem Cell Therapy | Comments Off on The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

Posted: July 24, 2011 at 4:04 pm

CARLSBAD, Calif. (July 20, 2011) – International Stem Cell Corporation (OTCBB: ISCO) announced today the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells.


The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSC), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).

ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, and thus have the capacity to become almost any cell type in the body. 

However, unlike hESCs, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.


Because no human embryos are ever damaged or destroyed in creating ISCO’s cells, they also avoid the ethical issues associated with embryonic hESC cells. ISCO maintains the world’s largest collection of research-grade hpSC lines.
Dr. Andrey Semechkin, the CEO of ISCO, comments: “The ability of neuronal cells to become a specific
type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”
Parkinson’s disease is a disease of the central nervous system that affects millions of people worldwide.
PD patients present a range of possible symptoms, some of which are known to be as a result of the loss of dopaminergic neurons in the mid brain. ISCO’s approach is first to derive neuronal cells successfully from hpSC and, second, to evaluate their safety, functionality and efficacy using a series of in-house in vitro and in vivo models.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com .
To subscribe to receive ongoing corporate communications, please click on the following link: http://
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell
lines, and other opportunities for the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, Ph.D.
Vice President
or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
# # #

Posted in Stem Cells, Stem Cell Therapy | Comments Off on International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

Meditation May Help Women Cope With Hot Flashes

Posted: July 24, 2011 at 4:03 pm

(HealthDay News) -- An easy-to-learn meditation technique can help ease the hot flashes, night sweats and insomnia of menopause, a new study says.

The University of Massachusetts research showed that mindfulness training, based on a Buddhist meditation concept, reduced the distress associated with hot flashes and improved physical, psychosocial and sexual functioning.

"The findings are important because hormone replacement therapy, used to treat menopause symptoms in the past, has been associated with health risks," said study author James Carmody, an associate professor of medicine in the division of preventive and behavioral medicine.

About 40 percent of menopausal women suffer from hot flashes and night sweats, which undermine their quality of life, the researchers noted. But since hormone replacement therapy has been linked with an increased risk of heart disease, breast cancer and stroke, Carmody observed that "not only are women looking for alternative treatments, it is an NIH (National Institutes of Health) priority to find behavioral treatments Read more...

Cardiofy Heart Care Supplement

Posted in Integrative Medicine | Comments Off on Meditation May Help Women Cope With Hot Flashes

New Report Details Uphill Battle to Solve the U.S.'s Pain Problem

Posted: July 24, 2011 at 4:03 pm

Chronic pain affects at least one in three adults in the U.S., which is more than the sum total of those with heart disease, cancer and diabetes combined. For many of these 116 million Americans, their pain is severe and eludes available treatments. In addition to the human suffering, the monetary cost of medical treatment and lost productivity has reached $635 billion a year. [More]

Add to digg
Add to StumbleUpon
Add to Reddit
Add to Facebook
Add to del.icio.us
Email this Article


Posted in Gene therapy | Comments Off on New Report Details Uphill Battle to Solve the U.S.'s Pain Problem

The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

Posted: July 24, 2011 at 4:03 pm

International Stem Cell Corp (OTCBB: ISCO), a biotechnology company focused on therapeutic biomedical research and cosmeceutical products, operating in the same industry as companies like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC), aims to become the premier supplier of human cells and cell based products to the rapidly growing regenerative medicine industry.
International Stem Cell Corp (OTCBB: ISCO) specializes in manufacturing pluripotent human “partheno-genetic” stem cells that can be converted into any of the many specific types of cells that will be needed as regenerative medicine moves from the laboratory to the hospital or physician’s office.  ISCO’s cells have the same kind of ability to become any specific cell that might be needed for therapy as do the cells used by competitors like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC). Unlike the cells used by these competitors, however, ISCO’s cells are not obtained from fertilized embryos that might otherwise mature into a human child. Instead, they are derived from un-fertilized human eggs that would otherwise be destroyed and have no capacity to become a human child. Thus, ISCO’s parthenogenetic stem cells have removed a major ethical barrier to the use of the most prolific class of stem cells available to science today. With its patent on using the parthenogenesis process to make the stem cells, the company plans to establish partnerships, collaborations and licensing agreements with larger pharmaceutical companies to eventually unlock significant shareholder value.
Please read the complete article at The OTC Investor here
Posted in Stem Cells, Stem Cell Therapy | Comments Off on The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper

International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

Posted: July 24, 2011 at 4:03 pm

CARLSBAD, Calif. (July 20, 2011) – International Stem Cell Corporation (OTCBB: ISCO) announced today the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells.


The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSC), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).

ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, and thus have the capacity to become almost any cell type in the body. 

However, unlike hESCs, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.


Because no human embryos are ever damaged or destroyed in creating ISCO’s cells, they also avoid the ethical issues associated with embryonic hESC cells. ISCO maintains the world’s largest collection of research-grade hpSC lines.
Dr. Andrey Semechkin, the CEO of ISCO, comments: “The ability of neuronal cells to become a specific
type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”
Parkinson’s disease is a disease of the central nervous system that affects millions of people worldwide.
PD patients present a range of possible symptoms, some of which are known to be as a result of the loss of dopaminergic neurons in the mid brain. ISCO’s approach is first to derive neuronal cells successfully from hpSC and, second, to evaluate their safety, functionality and efficacy using a series of in-house in vitro and in vivo models.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com .
To subscribe to receive ongoing corporate communications, please click on the following link: http://
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell
lines, and other opportunities for the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, Ph.D.
Vice President
or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
# # #

Posted in Stem Cells, Stem Cell Therapy | Comments Off on International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells

CIRM Bridges: Training the Next Generation of Stem Cell Scientists

Posted: July 23, 2011 at 2:10 pm

The CIRM Bridges to Stem Cell Research Awards are training the next generation of stem cell scientists and laboratory technicians by funding courses and research internships for undergraduates and masters-level students. At the 2011 CIRM Bridges Trainee Meeting, 160 students from the 16 Bridges programs presented posters that describe the research results from their internships and learned about career opportunities in stem cell science.

View original post here:
CIRM Bridges: Training the Next Generation of Stem Cell Scientists

Posted in Stem Cell Videos | Comments Off on CIRM Bridges: Training the Next Generation of Stem Cell Scientists

Opening Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine

Posted: July 22, 2011 at 3:40 pm

Program Chair: Kelvin Lam, PhD, Harvard University, USA From the SBS Symposium Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine. Held in Boston, MA, USA - September 2-3, 2009.

Read the original:
Opening Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine

Posted in Regenerative Medicine | Comments Off on Opening Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine

Clinical Advances in Adult Stem Cell Therapy – Dr. Jorge Paz Rodriguez (Miami)

Posted: July 21, 2011 at 12:46 pm

Current treatments with Adipose-, Bone Marrow- and Cord Blood-derived stem cells. Autism, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis and Osteoarthritis treatments are outlined.

Here is the original post:
Clinical Advances in Adult Stem Cell Therapy - Dr. Jorge Paz Rodriguez (Miami)

Posted in Cell Therapy | Comments Off on Clinical Advances in Adult Stem Cell Therapy – Dr. Jorge Paz Rodriguez (Miami)

Page 2,982«..1020..2,9812,9822,9832,984..2,9903,000..»